Breaking News, Collaborations & Alliances

Merck, Taiho, Astex Enter Exclusive Research Alliance

To develop small molecule inhibitors against KRAS oncogene for the treatment of cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck has entered an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd. and Astex Pharmaceuticals (UK), a subsidiary of Otsuka Pharmaceutical Co., to develop small molecule inhibitors against several drug targets, including the KRAS oncogene, currently being investigated for the treatment of cancer. KRAS is among the most frequently mutated oncogenes in cancer. It’s estimated to occur in more than 90% of pancreatic cancers and approximately 20%...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters